{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T13:40:15Z","timestamp":1740490815261,"version":"3.38.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s12185-024-03764-6","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T07:03:46Z","timestamp":1711523026000},"page":"326-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent advances in understanding the biology of follicular lymphoma"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4171-2162","authenticated-orcid":false,"given":"Momoko","family":"Nishikori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"3764_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-immunol-120419-022408","volume":"40","author":"GD Victora","year":"2022","unstructured":"Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2022;40:413\u201342.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"3764_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","volume":"5","author":"A Carbone","year":"2019","unstructured":"Carbone A, Roulland S, Gloghini A, et al. Follicular lymphoma. Nat Rev Dis Primers. 2019;5(1):83.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"3764_CR3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41590-018-0181-4","volume":"19","author":"P Milpied","year":"2018","unstructured":"Milpied P, Cervera-Marzal I, Mollichella ML, et al. Human germinal center transcriptional programs are de-synchronized in B cell lymphoma. Nat Immunol. 2018;19(9):1013\u201324.","journal-title":"Nat Immunol"},{"issue":"4","key":"3764_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nrc.2017.127","volume":"18","author":"S Huet","year":"2018","unstructured":"Huet S, Sujobert P, Salles G. From genetics to the clinic: a translational perspective on follicular lymphoma. Nat Rev Cancer. 2018;18(4):224\u201339.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3764_CR5","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/bjh.17383","volume":"194","author":"E Kumar","year":"2021","unstructured":"Kumar E, Pickard L, Okosun J. Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation. Br J Haematol. 2021;194(5):810\u201321.","journal-title":"Br J Haematol"},{"issue":"5","key":"3764_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","volume":"23","author":"W B\u00e9guelin","year":"2013","unstructured":"B\u00e9guelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677\u201392.","journal-title":"Cancer Cell"},{"issue":"10","key":"3764_CR7","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/nm.3940","volume":"21","author":"J Zhang","year":"2015","unstructured":"Zhang J, Dominguez-Sola D, Hussein S, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. 2015;21(10):1190\u20138.","journal-title":"Nat Med"},{"issue":"3","key":"3764_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1158\/2159-8290.CD-16-1417","volume":"7","author":"J Zhang","year":"2017","unstructured":"Zhang J, Vlasevska S, Wells VA, et al. The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma. Cancer Discov. 2017;7(3):322\u201337.","journal-title":"Cancer Discov"},{"issue":"18","key":"3764_CR9","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","volume":"122","author":"C B\u00f6d\u00f6r","year":"2013","unstructured":"B\u00f6d\u00f6r C, Grossmann V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122(18):3165\u20138.","journal-title":"Blood"},{"issue":"2","key":"3764_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/ng.518","volume":"42","author":"RD Morin","year":"2010","unstructured":"Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181\u20135.","journal-title":"Nat Genet"},{"issue":"2","key":"3764_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ng.2856","volume":"46","author":"J Okosun","year":"2014","unstructured":"Okosun J, B\u00f6d\u00f6r C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46(2):176\u201381.","journal-title":"Nat Genet"},{"issue":"4","key":"3764_CR12","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","volume":"9","author":"D Ennishi","year":"2019","unstructured":"Ennishi D, Takata K, B\u00e9guelin W, et al. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov. 2019;9(4):546\u201363.","journal-title":"Cancer Discov"},{"key":"3764_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.molimm.2020.01.006","volume":"119","author":"Y Otsuka","year":"2020","unstructured":"Otsuka Y, Nishikori M, Arima H, et al. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. Mol Immunol. 2020;119:35\u201345.","journal-title":"Mol Immunol"},{"issue":"11","key":"3764_CR14","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1111\/cas.15122","volume":"112","author":"H Yuan","year":"2021","unstructured":"Yuan H, Nishikori M, Otsuka Y, Arima H, Kitawaki T, Takaori-Kondo A. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17\/TARC in B-cell lymphoma and enhances T-cell recruitment. Cancer Sci. 2021;112(11):4604\u201316.","journal-title":"Cancer Sci"},{"issue":"6","key":"3764_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s12185-022-03466-x","volume":"116","author":"Y Wang","year":"2022","unstructured":"Wang Y, Bui T, Zhang Y. The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy. Int J Hematol. 2022;116(6):837\u201345.","journal-title":"Int J Hematol"},{"issue":"1","key":"3764_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/imr.12983","volume":"302","author":"C Lamaison","year":"2021","unstructured":"Lamaison C, Tarte K. B cell\/stromal cell crosstalk in health, disease, and treatment: follicular lymphoma as a paradigm. Immunol Rev. 2021;302(1):273\u201385.","journal-title":"Immunol Rev"},{"issue":"21","key":"3764_CR17","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159\u201369.","journal-title":"N Engl J Med"},{"issue":"22","key":"3764_CR18","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1182\/bloodadvances.2016000786","volume":"1","author":"CR Bolen","year":"2017","unstructured":"Bolen CR, McCord R, Huet S, et al. Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood Adv. 2017;1(22):1884\u201390.","journal-title":"Blood Adv"},{"issue":"4","key":"3764_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","volume":"19","author":"S Huet","year":"2018","unstructured":"Huet S, Tesson B, Jais JP, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018;19(4):549\u201361.","journal-title":"Lancet Oncol"},{"issue":"20","key":"3764_CR20","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.1182\/blood-2011-04-345777","volume":"118","author":"C Laurent","year":"2011","unstructured":"Laurent C, M\u00fcller S, Do C, et al. Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood. 2011;118(20):5371\u20139.","journal-title":"Blood"},{"issue":"34","key":"3764_CR21","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1200\/JCO.2006.06.4766","volume":"24","author":"T Alvaro","year":"2006","unstructured":"Alvaro T, Lejeune M, Salvad\u00f3 MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006;24(34):5350\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3764_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1158\/1078-0432.CCR-09-2487","volume":"16","author":"BE Wahlin","year":"2010","unstructured":"Wahlin BE, Aggarwal M, Montes-Moreno S, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1\u2013positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res. 2010;16(2):637\u201350.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"3764_CR23","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331\u201344.","journal-title":"N Engl J Med"},{"issue":"19","key":"3764_CR24","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1182\/blood.2020008119","volume":"137","author":"CR Bolen","year":"2021","unstructured":"Bolen CR, Mattiello F, Herold M, et al. Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma. Blood. 2021;137(19):2704\u20137.","journal-title":"Blood"},{"issue":"7","key":"3764_CR25","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1182\/blood.V99.7.2562","volume":"99","author":"D Zhu","year":"2002","unstructured":"Zhu D, McCarthy H, Ottensmeier CH, Johnson P, Hamblin TJ, Stevenson FK. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood. 2002;99(7):2562\u20138.","journal-title":"Blood"},{"issue":"43","key":"3764_CR26","doi-asserted-by":"publisher","first-page":"18587","DOI":"10.1073\/pnas.1009388107","volume":"107","author":"V Coelho","year":"2010","unstructured":"Coelho V, Krysov S, Ghaemmaghami AM, et al. Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proc Natl Acad Sci U S A. 2010;107(43):18587\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"3764_CR27","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1182\/blood-2015-04-640912","volume":"126","author":"R Amin","year":"2015","unstructured":"Amin R, Mourcin F, Uhel F, et al. DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. Blood. 2015;126(16):1911\u201320.","journal-title":"Blood"},{"issue":"16","key":"3764_CR28","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1182\/blood-2015-04-640805","volume":"126","author":"A Linley","year":"2015","unstructured":"Linley A, Krysov S, Ponzoni M, Johnson PW, Packham G, Stevenson FK. Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells. Blood. 2015;126(16):1902\u201310.","journal-title":"Blood"},{"issue":"19","key":"3764_CR29","doi-asserted-by":"publisher","first-page":"5812","DOI":"10.1182\/bloodadvances.2023010725","volume":"7","author":"CAM van Bergen","year":"2023","unstructured":"van Bergen CAM, Kloet SL, Quinten E, et al. Acquisition of a glycosylated B-cell receptor drives follicular lymphoma toward a dark zone phenotype. Blood Adv. 2023;7(19):5812\u20136.","journal-title":"Blood Adv"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03764-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03764-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03764-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T12:42:56Z","timestamp":1740487376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03764-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3764"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03764-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"assertion":[{"value":"14 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author has received research funding from SymBio Pharmaceuticals Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}